Skip to main content

Advertisement

SpringerLink
Log in

Anabolic therapy for osteoporosis: Parathyroid hormone

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Recombinant human parathyroid hormone (PTH 1–34) is the only anabolic agent currently approved for the treatment of osteoporosis. The term anabolic is based on mechanism of action. PTH stimulates bone formation, in contrast to antiresorptive agents, which reduce bone resorption and formation. Recent investigations involving the PTH(1-34) and PTH(1-84) peptides, alone and in combination or sequential regimens with antiresorptive agents, have provided a greater understanding of the place of PTH in the armamentarium against osteoporosis. These studies indicate that adding a bisphosphonate to PTH in previously untreated individuals does not produce additional bone benefit; however, sequential use of PTH followed-up by an antiresorptive agent is highly effective at increasing bone mineral density. Adding PTH after an antiresorptive agent also produces substantial bone density increments, though the magnitude of bone density increase may differ for different antiresorptive agents. PTH can repair underlying micro-architectural defects in bone, improve bone mass substantially, and perhaps change macro-architecture and geometry of bone. There are still many unanswered questions regarding PTH treatment of osteoporosis, including the optimal duration of treatment, optimal dosing regimen, mechanism of resistance to its effect after 18–24 months, and the effect of subsequent rechallenge.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. McClung MR, San Martin J, Miller PD, et al.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005, 165:1762–1768. This study describes biochemical, bone density, clinical, and histomorphometric differences between alendronate and teriparatide and highlight how different mechanisms of action are.

    Article  PubMed  CAS  Google Scholar 

  2. Arlot M, Meunier PJ, Boivin G, et al.: Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244–1253. This study describes biochemical, bone density, clinical, and histomorphometric differences between alendronate and teriparatide and highlight how different mechanisms of action are.

    Article  PubMed  CAS  Google Scholar 

  3. Chavassieux PM, Arot ME, Reda C, et al.: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475–1480. This paper describes histomorphometric.ndings from a subset of subjects enrolled in the Fracture Prevention Trial and highlights the microarchitectural benefits of teriparatide aon cancellous and cortical bone.

    Article  PubMed  CAS  Google Scholar 

  4. Boivin GY, Chavassieux PM, Santora AC, et al.: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687–694.

    Article  PubMed  CAS  Google Scholar 

  5. Roschger P, Rinnerthaler S, Yates J, et al.: Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185–191.

    Article  PubMed  CAS  Google Scholar 

  6. Jiang Y, Zhao JJ, Mitlak BH, et al.: Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932–1941.

    Article  PubMed  CAS  Google Scholar 

  7. Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846–1853.

    Article  PubMed  CAS  Google Scholar 

  8. Parfitt AM: PTH and Periosteal Bone Expansion. J Bone Miner Res 2002, 17:1741–1743.

    Article  PubMed  CAS  Google Scholar 

  9. Burr D: Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 2005, 3:19–24.

    Article  PubMed  Google Scholar 

  10. Rehman Q, Lang TF, Arnaud CD, et al.: Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003, 14:77–81.

    Article  PubMed  CAS  Google Scholar 

  11. Zanchetta JR, Bogado C, Ferretti JL, et al.: Effects of teriparatide [recombinant parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539–543.

    Article  PubMed  CAS  Google Scholar 

  12. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al.: Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948–958.

    Article  PubMed  CAS  Google Scholar 

  13. Body J-J, Gaich GA, Scheele WH, et al.: A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528–4535.

    Article  PubMed  CAS  Google Scholar 

  14. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441. This is the largest teriparatide study (n = 1637 women) and is the source of the fracture efficacy data for teriparatide.

    Article  PubMed  CAS  Google Scholar 

  15. Vahle JL, Sato M, Long GG, et al.: Skeletal changes in rats given daily subcutaneous injections of rhPTH(1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312–321.

    Article  PubMed  CAS  Google Scholar 

  16. Vahle JL, Long GG, Sandusky G, et al.: Bone neoplasms in F344 rats given teriparatide [rhPTH (1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426–438.

    Article  PubMed  CAS  Google Scholar 

  17. Marcus R, Wang O, Satterwhite J, Mitlak B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18–23.

    Article  PubMed  CAS  Google Scholar 

  18. Chen P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962–970.

    Article  PubMed  CAS  Google Scholar 

  19. Dobnig H, Sipos A, Jiang Y, et al.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970–3977.

    Article  PubMed  CAS  Google Scholar 

  20. Hodsman AB, Hanley DA, Ettinger MP, et al.: Efficacy and safety of human parathyroid hormone- (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212–5220.

    Article  PubMed  CAS  Google Scholar 

  21. Greenspan SL, Marriott TB, Hanley DA, et al.: Full-length PTH prevents.rst vertebral fracture in postmenopausal women with osteoporosis: results from the TOP study [abstract]. Amer College Rheumatol 2004, Suppl.

  22. Greenspan SL, Bone HG, Marriott TB, et al.: Preventing the.rst vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP study [abstract]. J Bone Miner Res 2005, 20(ppl 1):556.

    Google Scholar 

  23. Black DM, Rosen CM, Greenspan S, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207–1215. The PATH study compares PTH, alendronate, and their combination in women who have received no prior therapy.

    Article  PubMed  CAS  Google Scholar 

  24. Neer RM, Hayes A, Rao A, et al.: Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 2002, 17:(Supp 1):S135.

    Google Scholar 

  25. Cosman F, Nieves J, Woelfert L, et al.: Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998, 13:1051–1055.

    Article  PubMed  CAS  Google Scholar 

  26. Cosman F, Nieves J, Zaion M, et al.: Daily and Cylcic parathyroid hormone in women receiving alendronate. N Eng J Med 2005, 353:566–575. This trial evaluated women who had been treated with long term alendronate and showed that PTH can still produce a substantial bone density benefit in these patients. The study also suggests that cyclic PTH therapy is a valid option for future clinical trials.

    Article  CAS  Google Scholar 

  27. Ettinger B, San Martin J, Crans G, Pavo I: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745–751.

    Article  PubMed  CAS  Google Scholar 

  28. Lindsay R, Nieves J, Formica C, et al.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550–555.

    Article  PubMed  CAS  Google Scholar 

  29. Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925–931.

    Article  PubMed  CAS  Google Scholar 

  30. Roe EB, Sanchez SD, del Puerto GA, et al.: Parathyroid hormone 1–34 (hPTH 1–34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis — results from a placebo-controlled randomized trial [abstract]. J Bone Miner Res 1999, 12(ppl 1):S137.

    Google Scholar 

  31. Ste-Marie LG, Scheele WH, et al.: Effect of LY333334 [recombinant human parathyroid hormone (1–34), rhPTH(1-34)] on bone density when given to postmenopausal women receiving hormone replacement therapy (HRT) [abstract]. J Clin Endocrinol Metab 2001, 125:39509.

    Google Scholar 

  32. Deal C, Omizo M, Schwartz EN, et al.: Raloxifene in combination with teriparatide reduces teriparatideinduced stimulation of bone resorption but not formation in postmenopausal women with osteoporosis. J Bone Miner Res 2004, 19(ppl 1):S44.

    Google Scholar 

  33. Cosman F, Nieves J, Barbuto N, et al.: Parathyroid hormone added to raloxifene and subsequent maintenance of BMD gain with raloxifene alone. J Bone Miner Res 2004, 19(ppl 1):S98.

    Google Scholar 

  34. Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069–3076.

    Article  PubMed  CAS  Google Scholar 

  35. Orwoll ES, Scheele WH, Paul S, et al.: The effects of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9–17.

    Article  PubMed  CAS  Google Scholar 

  36. Kaufman JM, Orwoll E, Goemaere S, et al.: Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510–516.

    Article  PubMed  CAS  Google Scholar 

  37. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216–1226.

    Article  PubMed  CAS  Google Scholar 

  38. Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid- induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944–951.

    Article  PubMed  CAS  Google Scholar 

  39. Finkelstein JS, Klibanski A, Arnold AL, et al.: Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized, controlled trial. J Am Med Assoc 1998, 280:1067–1073.

    Article  CAS  Google Scholar 

  40. Lindsay R, Scheele WH, Neer R, et al.: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 164:2024–2030.

    Article  PubMed  Google Scholar 

  41. Kurland ES, Heller SL, Diamond B, et al.: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparitide [human parathyroid hormone (1-34)]. Osteoporo Int 2004, 15:992–997.

    Article  CAS  Google Scholar 

  42. Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129–2134.

    Article  PubMed  CAS  Google Scholar 

  43. Black DM, Bilezikian JP, Ensrud KE, et al.: One year of alendronate af ter one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555–565. The second year results from the PATH trial confirm in a randomized controlled study that antiresorptive agents are needed after 1 year of PTH to maintain PTH-induced benefifts.

    Article  PubMed  CAS  Google Scholar 

  44. Cosman F, Nieves J, Zion M, et al.: Effects of PTH(1-34) rechallenge 1 year after the.rst PTH course in patients on long-term alendronate [abstract]. J Bone Miner Res 2005, 20(ppl 1):S21.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Regional Bone Center, Helen Hayes Hospital, Route 9W, West Haverstraw, 10993, New York, NY, USA

    Felicia Cosman MD

Authors
  1. Felicia Cosman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felicia Cosman MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cosman, F. Anabolic therapy for osteoporosis: Parathyroid hormone. Curr Rheumatol Rep 8, 63–69 (2006). https://doi.org/10.1007/s11926-006-0028-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-006-0028-0

Keywords

Search

Navigation